Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Eli Lilly & Co. said Tuesday it’s cutting the ... a regulatory ruling that there’s no longer a shortage of weight-loss drugs that had allowed for alternatives to be made, sending the stock ...

Irish government mounts a St. Patrick’s Day diplomatic offensive to try and calm Trump anger at ‘massive’ trade surplus.

Roche is stepping into the hot weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). The Swiss pharmaceutical company has entered into an exclusive agreement with ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday.

By Rebecca Robbins It’s easy to make a medical case for blockbuster weight loss drugs like Wegovy and Zepbound ... the researchers concluded. And Eli Lilly’s Zepbound would be cost effective ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

first let's talk about the Eli Lilly story so far. It's important to remember that Lilly isn't only a weight loss drug company; it also sells a wide variety of products across treatment areas ...